{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:57:08Z","timestamp":1758815828228},"reference-count":235,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.eimc.2014.02.019","type":"journal-article","created":{"date-parts":[[2014,6,19]],"date-time":"2014-06-19T11:26:32Z","timestamp":1403177192000},"page":"446.e1-446.e42","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Documento de consenso de GeSIDA\/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualizaci\u00f3n enero 2014)"],"prefix":"10.1016","volume":"32","member":"78","reference":[{"key":"10.1016\/j.eimc.2014.02.019_bib0005","first-page":"329","article-title":"Recomendaciones de GESIDA\/Plan Nacional sobre el Sida respecto al tratamiento antirretrov\u00edrico en pacientes adultos infectados por el virus de la inmunodeficiencia humana en el a\u00f1o 2000 (I)","volume":"18","author":"Mir\u00f3","year":"2000","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2014.02.019_bib0010","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.2012.7961","article-title":"Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel","volume":"308","author":"Thompson","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2014.02.019_bib0015","unstructured":"Department of Human Health Service Panel on Antiretroviral Guidelines for Adults and Adolescents. Guideline for the use of antiretroviral agents in HIV-1-infected adults and adolescents: February 12, 2013 [consultado 17 Ene 2014]. Disponible en: http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf"},{"key":"10.1016\/j.eimc.2014.02.019_bib0020","unstructured":"European AIDS Clinical Society. Guidelines for the clinical management and treatment of HIV-infected adults in Europe (Version 7.0 October 2013) [consultado 19 Ene 2014]. Disponible en: http:\/\/www.eacsociety.org"},{"key":"10.1016\/j.eimc.2014.02.019_bib0025","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1086\/319366","article-title":"Guide to development of practice guidelines","volume":"32","author":"Kish","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"Supl 5","key":"10.1016\/j.eimc.2014.02.019_bib0030","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0213-005X(10)70048-3","article-title":"Indicadores de calidad asistencial de GESIDA para la atenci\u00f3n de personas infectadas por el VIH\/sida","volume":"28","author":"Von Wichmann","year":"2010","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2014.02.019_bib0035","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cit665","article-title":"Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America","volume":"58","author":"Aberg","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1293.2011.00971.x","article-title":"British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011","volume":"13","author":"Asboe","year":"2012","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0045","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1086\/520025","article-title":"Is the CD4 cell percentage a better marker of immunosuppression than the absolute CD4 cell count in HIV-infected patients with cirrhosis?","volume":"45","author":"Bongiovanni","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0050","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1056\/NEJM200101183440301","article-title":"A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04\/98","volume":"344","author":"L\u00f3pez Bernaldo de Quir\u00f3s","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0055","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(07)60948-9","article-title":"Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study","volume":"370","author":"Mocroft","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2014.02.019_bib0060","first-page":"41","article-title":"Optimal frequency of CD4 T cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients","volume":"10","author":"Kimmel","year":"2005","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0065","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1097\/QAI.0b013e31820472e8","article-title":"Clinical impact and cost of laboratory monitoring need review even in resource-rich setting","volume":"56","author":"Sayana","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2014.02.019_bib0070","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1086\/320192","article-title":"Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy","volume":"183","author":"Huang","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0075","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1086\/423388","article-title":"Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy","volume":"39","author":"Nettles","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0080","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jac\/dkm516","article-title":"Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome","volume":"61","author":"Garc\u00eda-Gasco","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2014.02.019_bib0085","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/QAI.0b013e31829f05ac","article-title":"Viral load monitoring as a tool to reinforce adherence: a systematic review","volume":"64","author":"Bonner","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2014.02.019_bib0090","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1086\/501458","article-title":"Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring","volume":"42","author":"Nettles","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0095","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1310\/4CCJ-KT1T-H6PV-NLFC","article-title":"Therapeutic drug monitoring in HIV treatment: A literature review","volume":"7","author":"Werteimer","year":"2011","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.eimc.2014.02.019_bib0100","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","article-title":"HIV-1 antiretroviral resistance. Scientific principles and clinical applications","volume":"72","author":"Tang","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.eimc.2014.02.019_bib0105","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1086\/589297","article-title":"Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA Panel","volume":"47","author":"Hirsch","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0110","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1473-3099(11)70032-9","article-title":"Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): A European multicohort study","volume":"11","author":"Wittkop","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0115","doi-asserted-by":"crossref","first-page":"e5253","DOI":"10.1136\/bmj.e5253","article-title":"Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: Multicentre observational study","volume":"345","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.eimc.2014.02.019_bib0120","unstructured":"Chueca N, \u00c1lvarez M, Monge S, Rodr\u00edguez C, Stella N, P\u00e9rez-El\u00edas MJ, et al. Transmisi\u00f3n de cepas con mutaciones de resistencia en los pacientes naive de CoRIS en el periodo 2011-13. Resistencia a f\u00e1rmacos de primera l\u00ednea. Programa y res\u00famenes del V Congreso Nacional de GeSIDA. Sitges, 19-22 de noviembre de 2013. Abstract P-111."},{"key":"10.1016\/j.eimc.2014.02.019_bib0125","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jama.2011.375","article-title":"Low frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: A systematic review and pooled analysis","volume":"305","author":"Li","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2014.02.019_bib0130","first-page":"77","article-title":"European recommendations for the clinical use of HIV drug resistance testing: 2011 update","volume":"13","author":"Vandamme","year":"2011","journal-title":"AIDS Rev"},{"key":"10.1016\/j.eimc.2014.02.019_bib0135","first-page":"247","article-title":"Interpretation of resistance data from randomized trials of first-line antiretroviral treatment","volume":"14","author":"Clotet","year":"2012","journal-title":"AIDS Rev"},{"key":"10.1016\/j.eimc.2014.02.019_bib0140","first-page":"6","article-title":"Update of the drug resistance mutations in HIV-1: March 2013","volume":"21","author":"Johnson","year":"2013","journal-title":"Top Antivir Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0145","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1345\/aph.1K522","article-title":"Abacavir hypersensitivity reaction: An update","volume":"42","author":"Hughes","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.eimc.2014.02.019_bib0150","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLAB*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0155","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1086\/529382","article-title":"High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically. confirmed abacavir hypersensitivity in white and black patients","volume":"46","author":"Saag","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0160","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1742-4690-7-56","article-title":"Comparative determination of HIV-1 co-receptor tropism by enhanced sensitivity profile, gp120 V3-loop RNA and DNA genotyping","volume":"7","author":"Prosperi","year":"2010","journal-title":"Retrovirology"},{"key":"10.1016\/j.eimc.2014.02.019_bib0165","first-page":"135","article-title":"Genotypic determination of HIV tropism-clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists","volume":"12","author":"Poveda","year":"2010","journal-title":"AIDS Rev"},{"key":"10.1016\/j.eimc.2014.02.019_bib0170","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S1473-3099(10)70319-4","article-title":"European guidelines on the clinical management of HIV-1 tropism testing","volume":"11","author":"Vandekerckhove","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0175","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1086\/586713","article-title":"Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study","volume":"197","author":"Emery","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0180","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1056\/NEJMoa0910370","article-title":"Early versus standard antiretroviral therapy for HIV-infected adults in Haiti","volume":"363","author":"Severe","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0185","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(09)60612-7","article-title":"Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: A collaborative analysis of 18 HIV cohort studies","volume":"373","author":"Sterne","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2014.02.019_bib0190","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1056\/NEJMoa0807252","article-title":"Effect of early versus deferred antiretroviral therapy for HIV on survival","volume":"360","author":"Kitahata","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0195","doi-asserted-by":"crossref","first-page":"509","DOI":"10.7326\/0003-4819-154-8-201104190-00001","article-title":"When to initiate combined antiretroviral therapy to reduce mortality and AIDS defining illness in HIV-infected persons in developed countries: An observational study","volume":"154","author":"Cain","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0200","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1001\/archinternmed.2011.401","article-title":"Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters","volume":"171","year":"2011","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0205","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"Cohen","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0210","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0140-6736(10)60936-1","article-title":"Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: A population-based study","volume":"376","author":"Montaner","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2014.02.019_bib0215","doi-asserted-by":"crossref","first-page":"b1649","DOI":"10.1136\/bmj.b1649","article-title":"Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: Prospective cohort study","volume":"338","author":"Wood","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.eimc.2014.02.019_bib0220","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa0906768","article-title":"Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy","volume":"361","author":"Sax","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0225","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/infdis\/jir505","article-title":"Abacavir\/lamivudine versus tenofovir DF\/emtricitabine as part of combination regimens for initial treatment of HIV: Final results","volume":"204","author":"Sax","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0230","doi-asserted-by":"crossref","first-page":"445","DOI":"10.7326\/0003-4819-154-7-201104050-00316","article-title":"Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1","volume":"154","author":"Daar","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0235","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/QAI.0b013e3181dd911e","article-title":"Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir\/lamivudine versus tenofovir\/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study","volume":"55","author":"Post","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2014.02.019_bib0240","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/QAD.0b013e32832cbcc2","article-title":"Randomized, double-blind, placebo-matched, multicenter trial of abacavir\/lamivudine or tenofovir\/emtricitabine with lopinavir\/ritonavir for initial HIV treatment","volume":"23","author":"Smith","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.019_bib0245","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir\/lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0250","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"381","author":"Raffi","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2014.02.019_bib0255","unstructured":"Feinberg J, Clotet B, Khuong MA, Antinori A, van Lunzen J, Dumitru I, et al. Once-Daily Dolutegravir (DTG) Is Superior to Darunavir\/Ritonavir (DRV\/r) in Antiretroviral-Naive Adults: 48 Week Results From FLAMINGO (ING114915). 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Denver, September 10-13, 2013. Abstract H-1454a."},{"key":"10.1016\/j.eimc.2014.02.019_bib0260","unstructured":"Cruciani M, Mengoli C, Malena M, Parisi SG, Bosco O, Moyle G. Comparative virologic efficacy of Abacavir\/Lamivudine (ABC\/3TC) and Tenofovir\/Emtricitabine (TDF\/FTC): systematic review and metaregression of randomized clinical trials. 14th European AIDS Conference, Brussels, 16-19 October 2013. Abstract PE 7\/2."},{"key":"10.1016\/j.eimc.2014.02.019_bib0265","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(11)60936-7","article-title":"Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial","volume":"378","author":"Molina","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2014.02.019_bib0270","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(11)60983-5","article-title":"Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): A phase 3, randomised, non-inferiority trial","volume":"378","author":"Cohen","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2014.02.019_bib0275","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1310\/hct1403-81","article-title":"Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine\/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies","volume":"14","author":"Nelson","year":"2013","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.eimc.2014.02.019_bib0280","unstructured":"Cohen C, Wohl D, Arribas J, Henry K, van Lunzen J, Bloch M, et al. STaR Study: Single-Tablet Regimen Rilpivirine\/Emtricitabine\/Tenofovir DF Maintains Non-Inferiority to Efavirenz\/Emtricitabine\/Tenofovir DF in ART-Na\u00efve Adults Week 96 Results. 14th European AIDS Conference, Brussels, 16-19 October 2013. Abstract LBPE 7\/17."},{"key":"10.1016\/j.eimc.2014.02.019_bib0285","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":"Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study","volume":"363","author":"Van Leth","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2014.02.019_bib0290","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa074609","article-title":"Class-sparing regimens for initial treatment of HIV-1 infection","volume":"358","author":"Riddler","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0295","first-page":"36","article-title":"Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule\/ritonavir in antiretroviral-naive, HIV-infected patients","volume":"8","author":"Montaner","year":"2006","journal-title":"MedGenMed"},{"key":"10.1016\/j.eimc.2014.02.019_bib0300","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/01.qai.0000243092.40490.26","article-title":"Long-term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir\/ritonavir, or stavudine","volume":"43","author":"Bartlett","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2014.02.019_bib0305","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/QAI.0b013e31828ace69","article-title":"Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir\/emtricitabine in treatment-naive HIV-1-infected patients: Final 5-year results from STARTMRK","volume":"63","author":"Rockstroh","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2014.02.019_bib0310","unstructured":"Wohl D, Cohen C, Gallant JE, Mills A, Sax P, DeJesus E, et al. Elvitegravir\/Cobicistat\/Emtricitabine\/Tenofovir DF (STB) has Durable Efficacy and Differentiated Long-Term Safety and Tolerability Versus Efavirenz\/Emtricitabine\/Tenofovir DF (ATR) at Week 144 in Treatment-Na\u00efve HIV Patients. Program and Abstracts of the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 10-13, 2013; Denver, Colorado. Abstract H-672a."},{"key":"10.1016\/j.eimc.2014.02.019_bib0315","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3851\/IMP1745","article-title":"Nevirapine versus atazanavir\/ritonavir, each combined with tenofovir disoproxil fumarate\/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial","volume":"16","author":"Soriano","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2014.02.019_bib0320","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(06)69155-1","article-title":"The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: A randomised non-inferiority trial","volume":"368","author":"Eron","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2014.02.019_bib0325","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/QAI.0b013e318198a815","article-title":"Gemini: A noninferiority study of saquinavir\/ritonavir versus lopinavir\/ritonavir as initial HIV-1 therapy in adults","volume":"50","author":"Walmsley","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2014.02.019_bib0330","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/QAI.0b013e3181c990bf","article-title":"Once-daily atazanavir\/ritonavir compared with twice-daily lopinavir\/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study","volume":"53","author":"Molina","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2014.02.019_bib0335","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1468-1293.2012.01060.x","article-title":"Final 192-week efficacy and safety of once-daily darunavir\/ritonavir compared with lopinavir\/ritonavir in HIV-1-infected treatment-na\u00efve patients in the ARTEMIS trial","volume":"14","author":"Orkin","year":"2013","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0340","unstructured":"Clumeck N, Molina JM, Henry K, Gathe J, Rockstroh JK, DeJesus E, et al. Elvitegravir\/Cobicistat\/Emtricitabine\/Tenofovir DF (STB) has durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine\/tenofovir DF in treatment-na\u00efve HIV-1 infected patients: week 144 results. 14th European AIDS Conference, Brussels, 16-19 October 2013. Abstract LBPS 7\/2."},{"key":"10.1016\/j.eimc.2014.02.019_bib0345","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/infdis\/jit122","article-title":"Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine\/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: Week 48 results","volume":"208","author":"Gallant","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0350","unstructured":"Cahn P, the Gardel Study Group. Dual Therapy with Lopinavir\/ritonavir (LPV\/r) and Lamivudine (3TC) is non-inferior to standar triple drug therapy in na\u00efve HIV-1 infected subjects: 48-week results of the GARDEL Study. 14th European AIDS Conference, Brussels, 16-19 October 2013. Abstract LBPS 7\/6."},{"key":"10.1016\/j.eimc.2014.02.019_bib0355","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1089\/aid.2011.0275","article-title":"Lopinavir\/ritonavir combined with raltegravir or tenofovir\/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study","volume":"29","author":"Reynes","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.eimc.2014.02.019_bib0360","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S1473-3099(11)70196-7","article-title":"Raltegravir once daily or twice daily in previously untreated patients with HIV-1: A randomised, active-controlled, phase 3 non-inferiority trial","volume":"11","author":"Eron","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0365","doi-asserted-by":"crossref","first-page":"e31591","DOI":"10.1371\/journal.pone.0031591","article-title":"Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States","volume":"7","author":"Sax","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.eimc.2014.02.019_bib0370","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1097\/01.aids.0000247574.33998.03","article-title":"RAVE (Randomized Abacavir versus Viread Evaluation) Group UK. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy","volume":"20","author":"Moyle","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.019_bib0375","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/QAI.0b013e3181ae2eb9","article-title":"A randomized comparative trial of continued zidovudine\/lamivudine or replacement with tenofovir disoproxil fumarate\/emtricitabine in efavirenz-treated HIV-1-infected individuals","volume":"51","author":"Fisher","year":"2009","journal-title":"J Acquir Immune Defic Syndrom"},{"key":"10.1016\/j.eimc.2014.02.019_bib0380","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1086\/644769","article-title":"Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: A randomized, 96-week trial","volume":"49","author":"Martin","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0385","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/QAI.0b013e3181aa12d5","article-title":"A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir\/lamivudine or tenofovir\/emtricitabine in HIV-1-infected patients with virological suppression","volume":"51","author":"Martinez","year":"2009","journal-title":"J Acquir Immune Defic Syndrom"},{"key":"10.1016\/j.eimc.2014.02.019_bib0390","unstructured":"Moyle G, Orkin C, Fischer M, Dhar J, Anderson J, Ewan J, et al. Switching to Atripla (EFV\/FTC\/TDF) from Kivexa (ABC\/3TC)+efavirenz improves lipid levels towards NCEP recommendations: results of a 24-week randomized study. Program and abstracts of the XVIII International AIDS Conference; July 18-23, 2010; Vienna, Austria. Abstract THPE0133."},{"key":"10.1016\/j.eimc.2014.02.019_bib0395","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/cid\/cis1203","article-title":"SWIFT: Prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine\/tenofovir from lamivudine\/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen","volume":"56","author":"Campo","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0400","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3851\/IMP2305","article-title":"Switching to tenofovir\/emtricitabine from abacavir\/lamivudine in HIV-infected adults with raised cholesterol: Effect on lipid profiles","volume":"17","author":"Behrens","year":"2012","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2014.02.019_bib0405","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/infdis\/jir188","volume":"203","author":"McComsey","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0410","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/656417","article-title":"Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study","volume":"51","author":"Stellbrink","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0415","unstructured":"Negredo E, Domingo P, P\u00e9rez Alvarez N. Multicenter randomized study to assess changes in HIV subjects with low bone mineral density after switching from tenofovir to abacavir: OsteoTDF study. Program and abstracts of the 20th Conference on Retroviruses and Opportunistic Infections (CROI), March 3-6, 2013. Abstract."},{"issue":"Suppl 1","key":"10.1016\/j.eimc.2014.02.019_bib0420","first-page":"69","volume":"13","author":"Mills","year":"2013","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0425","unstructured":"Nelson M, Winston A, Waters L, Higgs C, Roche M, Mora-Peris B, et al. Multicentre open-label study of switching from Atripla to Eviplera for possible efavirenz associated CNS toxicity. Program and abstracts of the 53rd International Conference on Antimicrobial Agents and Chemotherapy; September 10-13, 2013. Denver. Abstract H-672b."},{"key":"10.1016\/j.eimc.2014.02.019_bib0430","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/QAD.0b013e328341685b","article-title":"A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine","volume":"25","author":"Waters","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.019_bib0435","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/QAD.0b013e32833f9f63","article-title":"A randomized crossover study to compare efavirenz and etravirine treatment","volume":"25","author":"Nguyen","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.019_bib0440","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1468-1293.2008.00597.x","article-title":"Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia","volume":"9","author":"Laureillard","year":"2008","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0445","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1086\/652718","article-title":"Pharmacokinetics of the treatment switch from efavirenz to nevirapine","volume":"50","author":"Parienti","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0450","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/00002030-200402200-00029","article-title":"Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals","volume":"18","author":"Winston","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.019_bib0455","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1468-1293.2008.00552.x","article-title":"Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts","volume":"9","author":"De Lazzari","year":"2008","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0460","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1086\/528861","article-title":"Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: The ATHENA Cohort Study","volume":"46","author":"Wit","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0465","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1097\/QAD.0b013e32832d3b54","article-title":"Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy","volume":"23","author":"Kesselring","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.019_bib0470","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QAI.0b013e3181a572cf","article-title":"Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients","volume":"51","author":"DeJesus","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2014.02.019_bib0475","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1097\/QAD.0b013e32833bee1b","article-title":"Similar efficacy and tolerability of atazanavir compared with atazanavir\/ritonavir, each with abacavir\/lamivudine after initial suppression with abacavir\/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients","volume":"24","author":"Squires","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.019_bib0480","unstructured":"Wohl D, Bhatti L, Small CB, Edelstein H, Zhao HH, Margolis DA, et al. Simplification to abacavir\/lamivudine (ABC\/3TC)+atazanavir (ATV) from tenofovir\/emtricitabine (TDF\/FTC)+ATV\/ritonavir maintains viral suppression and improves bone biomarkers: 48 week ASSURE study results. Program and abstracts of the 53rd International Conference on Antimicrobial Agents and Chemotherapy; September 10-13, 2013. Denver. Abstract H-665."},{"key":"10.1016\/j.eimc.2014.02.019_bib0485","unstructured":"Bloch M, Tong W, Hoy J. Improved low BMD and bone turnover markers with switch from tenofovir to raltegravir in virologically suppressed HIV-1+ adults at 48 weeks: The TROP Study. Program and abstracts of the 19th Conference on Retroviruses and Opportunistic Infections; March 5-8, 2012 Seattle, WA. Abstract 878."},{"key":"10.1016\/j.eimc.2014.02.019_bib0490","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1097\/QAD.0b013e328348dab0","article-title":"A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study)","volume":"25","author":"Nguyen","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.019_bib0495","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1086\/605674","article-title":"Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: A randomized open-label trial","volume":"49","author":"De Castro","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0500","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1468-1293.2008.00627.x","article-title":"Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: A meta-analysis of randomized controlled trials","volume":"9","author":"Ena","year":"2008","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0505","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJMoa021589","article-title":"Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection","volume":"349","author":"Martinez","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0510","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/01.aids.0000171405.46113.bf","article-title":"Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine","volume":"19","author":"Fisac","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.019_bib0515","first-page":"5","article-title":"SPIRIT: Switching to emtricitabine\/rilpivirine\/tenofovir DF single-tablet regimen from boosted protease inhibitor maintains HIV suppression at week 48","volume":"1","author":"Fisher","year":"2012","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.eimc.2014.02.019_bib0520","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0140-6736(09)62041-9","article-title":"Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): Two multicentre, double-blind, randomised controlled trials","volume":"375","author":"Eron","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2014.02.019_bib0525","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1097\/QAD.0b013e32833a608a","article-title":"Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: The SPIRAL study","volume":"24","author":"Martinez","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.019_bib0530","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1468-1293.2012.00989.x","article-title":"The MONET trial: Week 144 analysis of the efficacy of darunavir\/ritonavir (DRV\/r) monotherapy versus DRV\/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load","volume":"13","author":"Arribas","year":"2012","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0535","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/QAI.0b013e3181a56de5","article-title":"Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis","volume":"51","author":"Arribas","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2014.02.019_bib0540","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1089\/aid.2011.0256","article-title":"No evidence for evolution of protease inhibitor resistance from standard genotyping, after three years of treatment with rarunavir\/ritonavir, with or without nucleoside analogues","volume":"28","author":"Pulido","year":"2012","journal-title":"AIDS Res Human Retroviruses"},{"key":"10.1016\/j.eimc.2014.02.019_bib0545","doi-asserted-by":"crossref","first-page":"e69493","DOI":"10.1371\/journal.pone.0069493","article-title":"Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy","volume":"8","author":"P\u00e9rez-Valero","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.eimc.2014.02.019_bib0550","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/jac\/dks102","article-title":"Interleukin-6, and C-reactive protein levels after 3 years of treatment with darunavir\/ritonavir monotherapy or darunavir\/ritonavir+two nucleoside reverse transcriptase inhibitors in the MONET trial","volume":"67","author":"Arribas","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2014.02.019_bib0555","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1310\/hct1401-45","article-title":"Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir\/ritonavir monotherapy versus triple therapy in the MONET trial","volume":"14","author":"Geretti","year":"2013","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.eimc.2014.02.019_bib0560","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/infdis\/jir518","article-title":"Factors associated with virological failure in HIV-1-infected patients receiving darunavir\/ritonavir monotherapy","volume":"204","author":"Lambert-Niclot","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0565","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/135965350901400210","article-title":"Risk factors for loss of virological suppression in patients receiving lopinavir\/ritonavir monotherapy for maintenance of HIV suppression","volume":"14","author":"Pulido","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2014.02.019_bib0570","unstructured":"Pulido F, Serrano O, Rivero A, Montes ML, Rubio R, L\u00f3pez Bernaldo de Quiros JC, et al. Atazanavir\/ritonavir monotherapy for maintenance of virologic suppression: 48---week primary analysis of the 96-week multicentre, open-label, single-arm, pilot OREY study. Program and abstracts of the 12th European AIDS Conference; Cologne, Germany, 2009. PS4\/6."},{"key":"10.1016\/j.eimc.2014.02.019_bib0575","unstructured":"Castagna A, Spagnuolo V, Galli L. 48-weeks outcomes of atazanavir\/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: Interim analysis results of the moDAT Study (nCT01511809). Program and abstracts of the 14th European AIDS Conference; October 16-19, 2013; Brussels, Belgium. Abstract PS4\/2."},{"key":"10.1016\/j.eimc.2014.02.019_bib0580","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/jac\/dkl092","article-title":"HIV-1 viral load blips are of limited clinical significance","volume":"57","author":"Lee","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2014.02.019_bib0585","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3851\/IMP2287","article-title":"Persistence of novel first-line antiretroviral regimes in a cohort of HIV-positive subjects, CoRIS 2008-2010","volume":"18","author":"Jarrin","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2014.02.019_bib0590","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-151-2-200907210-00003","article-title":"The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: A cohort study","volume":"151","author":"Palella","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0595","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1086\/600073","article-title":"Predictive value of HIV-1 genotypic resistance test interpretation algorithms","volume":"200","author":"Rhee","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0600","doi-asserted-by":"crossref","first-page":"e43882","DOI":"10.1371\/journal.pone.0043882","article-title":"Technical and regulatory shortcomings of the TaqMan version 1 HIV viral load assay","volume":"7","author":"Brumme","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.eimc.2014.02.019_bib0605","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eimc.2008.02.007","article-title":"Resistencias genot\u00edpicas en pacientes con VIH-1 y grados de viremia persistentemente bajos","volume":"27","author":"Parra-Ruiz","year":"2009","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2014.02.019_bib0610","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/infdis\/jir353","article-title":"Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy","volume":"204","author":"Taiwo","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0615","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/QAI.0b013e3182745ab0","article-title":"Low-level HIV viremia is associated with microbial translocation and inflammation","volume":"62","author":"Reus","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2014.02.019_bib0620","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1468-1293.2008.00644.x","article-title":"Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-na\u00efve, nonnucleoside reverse transcriptase inhibitor-experienced patients: Study TMC125-C227","volume":"9","author":"Ruxrungtham","year":"2008","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0625","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/QAD.0b013e328345ee95","article-title":"Week 48 analysis of once-daily vs. twice-daily darunavir\/ritonavir in treatment-experienced HIV-1-infected patients","volume":"25","author":"Cahn","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.019_bib0630","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(07)61049-6","article-title":"Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: A randomised controlled phase III trial","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2014.02.019_bib0635","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3851\/IMP2443","article-title":"A randomized comparison of second-line lopinavir\/ritonavir monotherapy versus tenofovir\/lamivudine\/lopinavir\/ritonavir in patients failing NNRTI regimens: The HIV STAR study","volume":"17","author":"Bunupuradah","year":"2012","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2014.02.019_bib0640","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/S0140-6736(13)61164-2","volume":"381","author":"Boyd","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2014.02.019_bib0645","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0140-6736(06)69154-X","volume":"368","author":"Hicks","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2014.02.019_bib0650","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/01.qai.0000185314.56556.c3","article-title":"Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials","volume":"40","author":"Nelson","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2014.02.019_bib0655","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(07)60497-8","article-title":"Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials","volume":"369","author":"Clotet","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2014.02.019_bib0660","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1097\/QAD.0b013e3283316a5e","article-title":"Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: Pooled 48 week analysis of two randomized, controlled trials","volume":"23","author":"Katlama","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.019_bib0665","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","article-title":"Maraviroc for previously treated patients with R5 HIV-1 infection","volume":"359","author":"Gulick","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0670","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection","volume":"359","author":"Steigbigel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0675","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/630210","article-title":"High rate of virologic suppression with raltegravir plus etravirine and darunavir\/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: Results of the ANRS 139 TRIO trial","volume":"49","author":"Yazdanpanah","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0680","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(11)70249-3","article-title":"Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: Randomised, double-blind, phase 3, non-inferiority study","volume":"12","author":"Molina","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0685","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: Week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2014.02.019_bib0690","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/jis750","article-title":"Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study","volume":"207","author":"Eron","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0695","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/01.aids.0000218542.08845.b2","article-title":"Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: A randomized pilot study (E-184V study)","volume":"20","author":"Castagna","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.019_bib0700","first-page":"e438","article-title":"Adherence to HAART: A systematic review of developed and developing nation patient reported barriers and facilitators","volume":"3","author":"Mills","year":"2006","journal-title":"PLoS One"},{"key":"10.1016\/j.eimc.2014.02.019_bib0705","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1468-1293.2011.00928.x","article-title":"Adherence to antiretroviral therapy: Factors independently associated with reported difficulty taking antiretroviral therapy in a national sample of HIV-positive Australians","volume":"12","author":"Grierson","year":"2011","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0710","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/QAI.0b013e31827ed678","article-title":"Relationships among neurocognitive status, medication adherence measured by pharmacy refill records, and virologic suppression in HIV-infected persons","volume":"62","author":"Andrade","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2014.02.019_bib0715","doi-asserted-by":"crossref","DOI":"10.1007\/s10461-013-0547-4","article-title":"A review of the role of food insecurity in adherence to care and treatment among adult and pediatric populations living with HIV and AIDS","author":"Young","year":"2013","journal-title":"AIDS Behav"},{"key":"10.1016\/j.eimc.2014.02.019_bib0720","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40266-013-0107-7","article-title":"Aging, antiretrovirals, and adherence: A meta-analysis of adherence among older HIV-infected individuals","volume":"30","author":"Ghidei","year":"2013","journal-title":"Drugs Aging"},{"key":"10.1016\/j.eimc.2014.02.019_bib0725","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1080\/09540121.2012.712667","article-title":"The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: A systematic review and meta-analysis","volume":"25","author":"Al-Dakkak","year":"2013","journal-title":"AIDS Care"},{"key":"10.1016\/j.eimc.2014.02.019_bib0730","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11904-007-0010-0","article-title":"Adherence-resistance relationships to combination HIV antiretroviral therapy","volume":"4","author":"Bangsberg","year":"2007","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.eimc.2014.02.019_bib0735","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/QAD.0b013e3282f366ff","article-title":"Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance","volume":"22","author":"Gardner","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.019_bib0740","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1097\/QAD.0b013e3283499cd9","article-title":"Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy","volume":"25","author":"Llibre","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.019_bib0745","doi-asserted-by":"crossref","first-page":"e003028","DOI":"10.1136\/bmjopen-2013-003028","article-title":"Association between daily antiretroviral pill burden and treatment adherence, hospitalization risk, and other healthcare utilization and costs in a US Medicaid population with HIV","volume":"3","author":"Cohen","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.eimc.2014.02.019_bib0750","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/QAI.0b013e3181d9a330","article-title":"Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: A meta-analysis and systematic review","volume":"54","author":"Hart","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2014.02.019_bib0755","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/QAD.0b013e32830285fb","article-title":"Efficacy and safety of once-daily darunavir\/ritonavir versus lopinavir\/ritonavir in treatment-naive HIV-1-infected patients at week 48","volume":"22","author":"Ortiz","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.019_bib0760","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/QAD.0b013e32835f1db0","article-title":"Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: A systematic review and meta-analysis","volume":"27","author":"Shubber","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.019_bib0765","doi-asserted-by":"crossref","first-page":"e66223","DOI":"10.1371\/journal.pone.0066223","article-title":"Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine Cohort, France, 2004-2012","volume":"8","author":"Morlat","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.eimc.2014.02.019_bib0770","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1097\/QAD.0b013e328357f5ed","article-title":"Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care","volume":"26","author":"Kalayjian","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.019_bib0775","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1310\/hct1405-224","article-title":"AIDS Clinical Trial Group 5142 Study Team. Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142","volume":"14","author":"Huang","year":"2013","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.eimc.2014.02.019_bib0780","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/QAD.0b013e32835192ae","article-title":"Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents","volume":"26","author":"Bedimo","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.019_bib0785","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/cid\/cir269","article-title":"Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era","volume":"53","author":"Bedimo","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0790","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/QAI.0b013e31826f993c","article-title":"No association of abacavir use with myocardial infarction: Findings of an FDA meta-analysis","volume":"61","author":"Ding","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2014.02.019_bib0795","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/infdis\/jit340","article-title":"Profile of leukocyte-endothelial cell interactions induced in venules and arterioles by nucleoside reverse-transcriptase inhibitors in vivo","volume":"208","author":"De Pablo","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0800","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/QCO.0b013e328320a849","article-title":"Cardiovascular disease and HIV infection: host, virus, or drugs","volume":"22","author":"Martinez","year":"2009","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0805","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/cid\/cis620","article-title":"Complicated atazanavir-associated cholelithiasis: A report of 14 cases","volume":"55","author":"Rakotondravelo","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0810","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/infdis\/jit043","article-title":"Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: The D:A:D study","volume":"207","author":"Ryom","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0815","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/cid\/cis621","article-title":"High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy","volume":"55","author":"Hamada","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0820","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1093\/jac\/dkt125","article-title":"High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients","volume":"68","author":"De Lastours","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2014.02.019_bib0825","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/QAD.0b013e328353b047","article-title":"Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals","volume":"26","author":"Scourfield","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.019_bib0830","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1212\/WNL.0b013e31821670fb","article-title":"Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients","volume":"76","author":"Ciccarelli","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.eimc.2014.02.019_bib0835","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1093\/jac\/dks176","article-title":"High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs","volume":"67","author":"Allavena","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2014.02.019_bib0840","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1517\/14740338.2012.712109","article-title":"Drug-induced gynecomastia: An evidence-based review","volume":"11","author":"Deepinder","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.eimc.2014.02.019_bib0845","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/QCO.0000000000000017","article-title":"Pharmacological considerations on the use of antiretrovirals in pregnancy","volume":"26","author":"Colbers","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0850","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/jac\/dks416","article-title":"Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: A cohort study","volume":"68","author":"Monteiro","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2014.02.019_bib0855","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/jac\/dkr248","article-title":"Ageing with HIV: Medication use and risk for potential drug-drug interactions","volume":"66","author":"Marzolini","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2014.02.019_bib0860","unstructured":"Tuset M, Mir\u00f3 JM, Codina C, Ribas J, editores. Gu\u00eda de interacciones farmacol\u00f3gicas en VIH [consultado 19 Ene 2014]. Disponible en: http:\/\/www.interaccionesvih.com"},{"key":"10.1016\/j.eimc.2014.02.019_bib0865","unstructured":"Back D, Gibbons S, Wilkins E, Burger D, Shapiro J, Marzolini C, et al., editores. HIV drug interactions website [consultado 19 Ene 2014]. Disponible en: http:\/\/www.hiv-druginteractions.org"},{"key":"10.1016\/j.eimc.2014.02.019_bib0870","unstructured":"Tseng A, Foisy M, editors. Drug interaction tables. Immunodeficiency Clinic, Toronto General Hospital [consultado 19 Ene 2014]. Disponible en: http:\/\/www.hivclinic.ca\/main\/drugs_interact.html"},{"key":"10.1016\/j.eimc.2014.02.019_bib0875","unstructured":"European Medicines Agency (EMA). European public assessment reports (EPAR) for human medicines [consultado 19 Ene 2014]. Disponible en: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/epar_search.jsp&mid=WC0b01ac058001d124"},{"key":"10.1016\/j.eimc.2014.02.019_bib0880","unstructured":"U.S. Food and Drug Administration FDA approved drug products [consultado 19 Ene 2014]. Disponible en: http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/default.htm"},{"key":"10.1016\/j.eimc.2014.02.019_bib0885","unstructured":"Back D, Khoo S, Seden K, Gibbons S, Burger D, Dietrich D, et al, editores. University of Liverpool [consultado 19 Ene 2014]. Disponible en: http:\/\/www.hep-druginteractions.org\/"},{"key":"10.1016\/j.eimc.2014.02.019_bib0890","unstructured":"Berenguer J, Calleja JL, Esteban R, Fern\u00e1ndez MJ, Forns X, Gonz\u00e1lez J, et al. Criterios y recomendaciones generales para el tratamiento con boceprevir y telaprevir de la hepatitis cr\u00f3nica C en pacientes infectados por el VIH, en trasplantados de h\u00edgado y en poblaci\u00f3n pedi\u00e1trica [consultado 19 Ene 2014]. Disponible en: http:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/medSituacionesEspeciales\/docs\/criterios-VHC-off-label.pdf"},{"key":"10.1016\/j.eimc.2014.02.019_bib0895","first-page":"602.e1","article-title":"Documento de consenso de GeSIDA\/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualizaci\u00f3n enero 2013)","volume":"31","year":"2013","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2014.02.019_bib0900","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1056\/NEJMra1011874","article-title":"Acute HIV-1 infection","volume":"364","author":"Cohen","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0905","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11904-012-0113-0","article-title":"Should we treat acute HIV infection?","volume":"9","author":"O\u2019Brien","year":"2012","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.eimc.2014.02.019_bib0910","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1001\/archinternmed.2012.2719","article-title":"Inmunovirologic control 24 months after interruption of antiretroviral therapy initiated closet o HIV seroconversion","volume":"172","author":"Lodi","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0915","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3851\/IMP2273","article-title":"HIV-1 control after transient antiretroviral treatment initiated in primary infection: Role of patient characteristics and effect of therapy","volume":"17","author":"Goujard","year":"2012","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2014.02.019_bib0920","doi-asserted-by":"crossref","first-page":"e1003211","DOI":"10.1371\/journal.ppat.1003211","article-title":"Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study","volume":"9","author":"S\u00e1ez-Ciri\u00f3n","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.eimc.2014.02.019_bib0925","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1056\/NEJMoa1110187","article-title":"Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy","volume":"368","author":"Le","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib0930","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/cid\/ciq248","article-title":"Update on human immunodeficiency virus (HIV)-2 infection","volume":"52","author":"Campbell-Yesufu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0935","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1097\/00126334-200412150-00001","article-title":"Phenotypic susceptibility to non-nucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups","volume":"37","author":"Tuaillon","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2014.02.019_bib0940","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1086\/597802","article-title":"Antiretroviral drug resistance in HIV-2: Three amino acid changes are sufficient for classwide nucleoside analogue resistance","volume":"199","author":"Smith","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0945","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1747-0285.2008.00647.x","article-title":"Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use","volume":"71","author":"Brower","year":"2008","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.eimc.2014.02.019_bib0950","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dkn335","article-title":"HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro","volume":"62","author":"Roquebert","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2014.02.019_bib0955","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1128\/JVI.72.7.5425-5432.1998","article-title":"Genetically divergent strains of human immunodeficiency virus type 2 use multiple coreceptors for viral entry","volume":"72","author":"Owen","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.eimc.2014.02.019_bib0960","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/088922204322996590","article-title":"Are fusion inhibitors active against all HIV variants","volume":"20","author":"Poveda","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.eimc.2014.02.019_bib0965","unstructured":"Grupo de expertos de la Secretar\u00eda del Plan Nacional sobre el Sida (SPNS), Grupo de Estudio del Sida (GESIDA), Sociedad Espa\u00f1ola de Ginecolog\u00eda y Obstetricia (SEGO) y Sociedad espa\u00f1ola de Infectolog\u00eda Pedi\u00e1trica\/SEIP). Gu\u00eda pr\u00e1ctica para el seguimiento de la infecci\u00f3n por VIH en relaci\u00f3n con la reproducci\u00f3n, embarazo, parto y profilaxis de la transmisi\u00f3n vertical del ni\u00f1o expuesto (2013) [consultado 19 Ene 2014]. Disponible en: http:\/\/www.gesida-seimc.org\/pcientifica\/fuentes\/DcyRc\/gesidadcyrc2013-SeguimientoInfVIHEmbarazo.pdf"},{"key":"10.1016\/j.eimc.2014.02.019_bib0970","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services [consultado 19 Ene 2014]. Disponible en: http:\/\/aidsinfo.nih.gov\/guidelines"},{"key":"10.1016\/j.eimc.2014.02.019_bib0975","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1097\/QAD.0b013e32834cdb71","article-title":"Safety of efavirenz in the first trimester of pregnancy: An updated systematic review and meta-analysis","volume":"25","author":"Ford","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.019_bib0980","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1089\/aid.2013.0059","article-title":"Use of raltegravir in late-presenting, HIV-infected pregnant women","volume":"29","author":"Nobrega","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.eimc.2014.02.019_bib0985","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/cid\/cit374","article-title":"Is intrapartum intravenous zidovudine for prevention of mother-to-child HIV-1 transmission still useful in the combination antiretroviral therapy era?","volume":"57","author":"Briand","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0990","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/cid\/cit601","article-title":"Safety of tenofovir during pregnancy for the mother and fetus: A systematic review","volume":"57","author":"Wang","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib0995","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/QCO.0b013e3283420f76","article-title":"Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections","volume":"24","author":"Lawn","year":"2011","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib1000","doi-asserted-by":"crossref","first-page":"e5575","DOI":"10.1371\/journal.pone.0005575","article-title":"Early antiretroviral therapy reduces AIDS progression\/death in individuals with acute opportunistic infections: A multicenter randomized strategy trial","volume":"4","author":"Zolopa","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.eimc.2014.02.019_bib1005","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/j.1469-0691.2012.03991.x","article-title":"Optimal timing for initiation of highly active antiretroviral therapy in treatment-naive human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: The experience of the PISCIS cohort","volume":"19","author":"Manzardo","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.eimc.2014.02.019_bib1010","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1086\/652652","article-title":"Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-Saharan Africa","volume":"50","author":"Makadzange","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib1015","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/cid\/cit019","article-title":"Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis","volume":"56","author":"Bisson","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib1020","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1056\/NEJMoa1110404","article-title":"Combination antifungal therapy for cryptococcal meningitis","volume":"368","author":"Day","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib1025","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.eimc.2013.02.001","article-title":"Recomendaciones de GESIDA\/Secretar\u00eda del Plan Nacional sobre el Sida para el tratamiento de la tuberculosis en adultos infectados por el virus de la inmunodeficiencia humana (actualizaci\u00f3n enero de 2013)","volume":"31","author":"Rivero","year":"2013","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2014.02.019_bib1030","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1056\/NEJMoa1014181","article-title":"Integration of antiretroviral therapy with tuberculosis treatment","volume":"365","author":"Abdool Karim","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib1035","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa1013911","article-title":"Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis","volume":"365","author":"Blanc","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib1040","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJMoa1013607","article-title":"Timing of antiretroviral therapy for HIV-1 infection and tuberculosis","volume":"365","author":"Havlir","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib1045","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3851\/IMP2483","article-title":"Plasma concentrations of efavirenz with a 600mg standard dose in Cambodian HIV-infected adults treated for tuberculosis with a body weight above 50kg","volume":"18","author":"Borand","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2014.02.019_bib1050","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1473-3099(13)70007-0","article-title":"Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: A randomised non-inferiority trial","volume":"13","author":"Bonnet","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib1055","unstructured":"Grinsztejn B, De Castro N, Arnold V, Veloso V, Morgado M, Pilotto JH, et al. The ANRS 12 180 REFLATE TB study group. A randomised trial to estimate efficacy and safety of 2 doses of raltegravir and efavirenz for treatment of HIV-TB co-infected patients. XIX International AIDS Conference. July 26, 2012. Abstract THLBB01."},{"key":"10.1016\/j.eimc.2014.02.019_bib1060","unstructured":"The European Medicines Agency (EMEA). Celsentri: EPAR - Product Information [consultado 25 Sep 2013]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es ES\/document library\/EPAR - Product Information\/human\/000811\/WC500022190.pdf"},{"key":"10.1016\/j.eimc.2014.02.019_bib1065","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ccm.2013.02.003","article-title":"Human immunodeficiency virus-associated tuberculosis: Update on prevention and treatment","volume":"34","author":"Dierberg","year":"2013","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.eimc.2014.02.019_bib1070","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1097\/QAD.0b013e32833dfc68","article-title":"Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome","volume":"24","author":"Meintjes","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.019_bib1075","first-page":"520.e1","article-title":"Diagn\u00f3stico, tratamiento y prevenci\u00f3n de las alteraciones renales en pacientes con infecci\u00f3n por el virus de la inmunodeficiencia humana. Recomendaciones del Grupo de Estudio del Sida\/Plan Nacional sobre el Sida","volume":"28","year":"2010","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2014.02.019_bib1080","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/hep.23136","article-title":"Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus\/hepatitis C virus","volume":"50","author":"Mac\u00edas","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2014.02.019_bib1085","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/hep.21757","article-title":"Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy","volume":"46","author":"Pineda","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2014.02.019_bib1090","doi-asserted-by":"crossref","first-page":"e68152","DOI":"10.1371\/journal.pone.0068152","article-title":"Suppression of HBV by tenofovir in HBV\/HIV coinfected patients: A systematic review and meta-analysis","volume":"8","author":"Price","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.eimc.2014.02.019_bib1095","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1310\/hct1302-61","article-title":"Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV\/HCV-coinfected patients","volume":"13","author":"Mac\u00edas","year":"2012","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.eimc.2014.02.019_bib1100","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1086\/512086","article-title":"Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C","volume":"195","author":"Barreiro","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib1105","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1128\/AAC.00632-09","article-title":"Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment","volume":"53","author":"P\u00e9rez-El\u00edas","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2014.02.019_bib1110","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/jac\/dkt386","article-title":"Raltegravir pharmacokinetics in HIV\/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C)","volume":"69","author":"Hern\u00e1ndez-Novoa","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2014.02.019_bib1115","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3851\/IMP2527","article-title":"Review of drug interactions with telaprevir and antiretrovirals","volume":"18","author":"Van Heeswijk","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2014.02.019_bib1120","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/cid\/cis968","article-title":"Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir","volume":"56","author":"Hulskotte","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib1125","unstructured":"Ficha t\u00e9cnica de Boceprevir [consultado 19 Ene 2014]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_Product_Information\/human\/002332\/WC500109786.pdf"},{"key":"10.1016\/j.eimc.2014.02.019_bib1130","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/QAI.0b013e318275da93","article-title":"Pharmacokinetic interaction between boceprevir and etravirine in HIV\/HCV seronegative volunteers","volume":"62","author":"Hammond","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2014.02.019_bib1135","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/cid\/cis824","article-title":"Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir","volume":"56","author":"de Kanter","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.019_bib1140","unstructured":"Vourvahis M, Plotka A, Kantaridis C, Fang A, Heera J. The effect of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers. 14th International Workshop on Clinical Pharmacology of HIV Therapy, April 22-24, 2013, Amsterdam. Abstract O-17."},{"key":"10.1016\/j.eimc.2014.02.019_bib1145","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1157\/13116574","article-title":"Recomendaciones de GESIDA\/PETHEMA sobre el diagn\u00f3stico y el tratamiento de los linfomas en pacientes infectados por el virus de la inmunodeficiencia humana","volume":"130","author":"Miralles","year":"2008","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.eimc.2014.02.019_bib1150","article-title":"Gu\u00eda de pr\u00e1ctica cl\u00ednica de tumores no definitorios de sida e infecci\u00f3n por el VIH","year":"2014","journal-title":"Enfer Infect Microbiol Clin"},{"key":"10.1016\/j.eimc.2014.02.019_bib1155","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.critrevonc.2008.10.013","article-title":"Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice","volume":"72","author":"Mounier","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.eimc.2014.02.019_bib1160","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S1470-2045(11)70056-0","article-title":"Use of antineoplastic agents in patients with cancer who have HIV\/AIDS","volume":"12","author":"Rudek","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eimc.2014.02.019_bib1165","unstructured":"Torres HA, Rallapalli V, Saxena A, Granwehr B, Viola G, Ariza E, et al. Efficacy and safety of antiretrovirals in HIV-infected patients with cancer. 53th Interscience Conference on Antimicrobial Agents and Chemotherapy. Denver 2013. Abstrac H2."},{"key":"10.1016\/j.eimc.2014.02.019_bib1170","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.eimc.2013.06.002","article-title":"An\u00e1lisis de costes y de coste\/eficacia de las pautas preferentes de GESIDA\/PlanNacional sobre el Sida en 2013 para el tratamiento antirretroviral inicial en adultos infectados por el virus de la inmunodeficiencia humana","volume":"31","author":"Blasco","year":"2013","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2014.02.019_bib1175","doi-asserted-by":"crossref","first-page":"e1001174","DOI":"10.1371\/journal.pmed.1001174","article-title":"The evolving landscape of the economics of HIV treatment and prevention","volume":"9","author":"Nosyk","year":"2012","journal-title":"PLoS Med"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X14000901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X14000901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T21:57:55Z","timestamp":1716847075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X14000901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":235,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0213005X14000901"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2014.02.019","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Documento de consenso de GeSIDA\/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualizaci\u00f3n enero 2014)","name":"articletitle","label":"Article Title"},{"value":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimc.2014.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.","name":"copyright","label":"Copyright"}]}}